Key result
BGP-15 improves diastolic function and reduces cardiomyocyte stiffness in atherosclerotic rabbits via the cGMP-PKG pathway.
Why the study?
BGP-15 was reported to alleviate heart failure symptoms and improve muscle function in murine models, but its acute and chronic effects in an atherosclerotic cardiomyopathy model remained to be investigated.
Does BGP-15 improve diastolic function in a rabbit model of atherosclerotic cardiomyopathy?
Does BGP-15 improve diastolic function in a rabbit model of atherosclerotic cardiomyopathy?
BGP-15 improves diastolic function and reduces cardiomyocyte stiffness in a rabbit model of atherosclerotic cardiomyopathy via the cGMP-PKG pathway.
BGP-15 merits testing in additional diastolic HF models; leaves open translation to human atherosclerotic cardiomyopathy.
No takes yet. Share an insight, caveat, or question.
Priksz et al. (2021) studied Atherosclerotic cardiomyopathy (rabbit model). BGP-15 vs. Standard chow (control) or atherogenic diet without BGP-15 was evaluated on Cardiac function, endothelium-dependent vasorelaxation, and PKG pathway molecules. BGP-15 treatment improved diastolic function, reduced cardiomyocyte stiffness, and restored titin compliance in a rabbit model of atherosclerotic cardiomyopathy via the cGMP-PKG pathway.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: